Abstract: The present invention relates to an oncolytic virus and the use thereof, specifically, an oncolytic virus having suppressed thymidine kinase (TK) gene expression and comprising genes encoding granulocyte-macrophage colony-stimulating factor (GM-CSF) and a complement regulatory protein; and the use of such an oncolytic virus. The oncolytic virus of the present invention maintains its efficacy even when administered intravenously, and thus, it may also be applied to the treatment of various solid cancers and metastatic cancers in addition to superficial solid cancers. In addition, the oncolytic virus of the present invention acquires resistance to complement attack by expressing a complement regulatory protein on the surface of the virus, and thus, it is stable in the blood, and it maintains stable oncolytic activity when intravenous injection, and thus, it may reduce effective viral dosage to minimize the side effects of anti-cancer drugs.

Abstract: The present invention relates to an anti-VISTA antibody or an antigen binding fragment thereof, a nucleic acid coding for the same, a vector carrying the nucleic acid, a cell transformed with the vector, a method for preparing the antibody or an antigen binding fragment thereof, a composition for prevention or treatment of autoimmune disease, comprising the same antibody, and a composition for concurrent administration in combination with a PD-1 antibody or PD-L1 antibody.

Abstract: Disclosed are an anti-PD-L1 antibody or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector including the nucleic acid, a cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, a pharmaceutical composition for preventing or treating cancer containing the same, and a composition for co-administration with an antibody other than an antibody binding to PD-L1, containing the same.

Abstract: Disclosed are an anti-PD-L1 antibody or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector including the nucleic acid, a cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, a pharmaceutical composition for preventing or treating cancer containing the same, and a composition for co-administration with an antibody other than an antibody binding to PD-L1, containing the same.

Abstract: The present invention relates to an anti-VISTA antibody or an antigen binding fragment thereof, a nucleic acid coding for the same, a vector carrying the nucleic acid, a cell transformed with the vector, a method for preparing the antibody or an antigen binding fragment thereof, a composition for prevention or treatment of autoimmune disease, comprising the same antibody, and a composition for concurrent administration in combination with a PD-1 antibody or PD-L1 antibody.